April 14, 2008

NanoScreen Introduces New Liquid Handling Robot At SBS 2008 In St. Louis

NanoScreen, LLC Release

CHARLESTON, SC – April 14, 2008 – NanoScreen, LLC, a global industry innovator in fluid dispensing products announced the release of the Libra[tm] Liquid Handling Workstation at the Society of Biomolecular Screening Conference in St Louis, Missouri.

The Libra[tm], NanoScreen's latest development, is a high performance bench-top liquid handling system offering superior reliability and a low cost entry point into 1536 pipetting. This system will offer industrial grade automation, enhanced reliability and an open access software interface.

"The Introduction of Libra[tm] levels the playing field for smaller biotech companies and R&D organizations by providing them cutting edge liquid handling capabilities at an affordable price point", said Daniel Dechert, NanoScreen's Chief Executive Officer.

"The Libra's design and functionality is based on over fifteen years of combined product observation and customer feedback", said Peter Hutchings, NanoScreen's Director of Global Sales.

The market for the Libra[tm] includes Pharmaceutical and Biotechnology companies along with Government and Private Research organizations across the world. The Libra[tm] will be utilized at many stages in the Drug Discovery and Drug Development process. Its ability to work in 96, 384 and 1536 formats opens the Libra[tm] to many applications. Further, the Libra[tm] can utilize NanoScreen's unique NS-1536 dispense head.

NanoScreen expects to start shipping systems in April, 2008 and have their first system order in process.

About NanoScreen:
NanoScreen, LLC is the leading edge developer and manufacturer of pipetting platforms and automated liquid handling consumables used in pharmaceutical R&D laboratories worldwide. NanoScreen's core competency is the manufacturing and validation of multi-channel dispensing units and the accompanying disposable pipette tips. NanoScreen's customers include research and industry leaders like Pfizer, GlaxoSmithKline (GSK), Merck, Johnson and Johnson (J&J), AstraZeneca, Amgen, Eli Lily, Sanofi-Aventis & Wyeth.

For more information about NanoScreen, visit http://www.nanoscreen.com.

Media Contact:
Daniel Dechert
President and CEO
843.881.8841
ddechert@nanoscreen.com

Sales Contact:
Peter Hutchings
Director of Global Sales
310.308.3504
phutchings@nanoscreen.com